Table I.
Baseline sorafenib after TACE patient's characteristics.
| Patient's characteristics | All patients (n=11) |
|---|---|
| Age (years), median (range) | 70.6±7.5 |
| Gender | |
| Male | 10 (90.9) |
| Female | 1 (9.1) |
| TTP, months | 3.9 (2.3–16.1) |
| OS, months | 34.4 (5.9–51.7) |
| Underlying cause | |
| HBV | 2 (18.2) |
| HCV | 6 (54.5) |
| NBNC | 3 (27.3) |
| ECOG performance score | |
| 0 | 10 (90.9) |
| 1 | 1 (9.1) |
| Child-Pugh score | |
| A | 11 (100.0) |
| B | 0 (0.0) |
| C | 0 (0.0) |
| LCSGJ staging | |
| II | 2 (18.2) |
| III | 9 (91.8) |
| AFP, ng/ml | 7.3 (3.5–188.0) |
| DCP, mAU/ml | 24.0 (8.0–3589.0) |
| Pretreatment HCC | |
| Yes | 11 (100.0) |
| No | 0 (0.0) |
| Initial sorafenib dose, mg | |
| 800 | 9 (91.8) |
| 400 | 2 (18.2) |
Categorical data are expressed as n (%). Continuous data are expressed as mean ± standard deviation or median (range) by group. HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, HBV (−) and HCV (−); ECOG, Eastern Cooperative Oncology Group; LCSGJ, Liver Cancer Study Group of Japan; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma. Child-Pugh score based on both clinical (ascites and encephalopathy) and laboratory (serum albumin, total bilirubin and prothrombin time) parameters.